Akela Pharma, Inc.

They are an integrated product development company primarily focused on therapeutics for pain utilizing their proprietary drug delivery technologies. Their lead product candidate is FentanylTAIFUN®, a fentanyl formulation specifically designed to be delivered with their TAIFUN® Multi-Dose Inhaler. They are developingFentanyl TAIFUN® as a rapid-acting inhaled opioid analgesic for treatment of break-through cancer pain. In June 2007, they entered into an exclusive license and development agreement with Janssen Pharmaceutica N.V. with respect the continuing development and commercialization of Fentanyl TAIFUN®. They believe, based upon the results of their clinical trials to date, that their Fentanyl TAIFUN® product candidate, if approved by regulatory agencies, will deliver much faster onset of pain relief from break-through cancer pain at lower dosages than other non-injectable products currently indicated for break-through cancer pain.

show less